UBS Group began coverage on shares of Avantor (NYSE:AVTR – Free Report) in a research note released on Wednesday morning, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $16.00 price objective on the stock.
Several other equities research analysts have also recently weighed in on the stock. Sanford C. Bernstein started coverage on shares of Avantor in a research report on Friday, June 26th. They issued a “market perform” rating and a $10.50 price target for the company. Wells Fargo & Company lifted their price objective on shares of Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Wolfe Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 30th. Wall Street Zen upgraded Avantor from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Stifel Nicolaus increased their target price on Avantor from $8.00 to $15.00 and gave the company a “hold” rating in a research report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $12.47.
Check Out Our Latest Analysis on Avantor
Avantor Stock Performance
Avantor (NYSE:AVTR – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. The company had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, equities research analysts forecast that Avantor will post 0.81 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Avantor by 28.1% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,123 shares of the company’s stock worth $49,000 after acquiring an additional 905 shares in the last quarter. Osaic Holdings Inc. boosted its stake in Avantor by 60.9% in the second quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock valued at $38,000 after acquiring an additional 1,064 shares in the last quarter. UMB Bank n.a. grew its holdings in Avantor by 17.6% in the fourth quarter. UMB Bank n.a. now owns 7,371 shares of the company’s stock worth $84,000 after purchasing an additional 1,101 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Avantor by 119.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after purchasing an additional 1,189 shares during the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in shares of Avantor by 0.6% during the third quarter. Public Employees Retirement System of Ohio now owns 206,386 shares of the company’s stock worth $2,576,000 after purchasing an additional 1,279 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.
Avantor Company Profile
Avantor, Inc (NYSE: AVTR) is a global provider of products and services used in the life sciences, healthcare and advanced technology industries. The company supports research, drug discovery, biopharmaceutical production, clinical and diagnostic activities, and other laboratory-based applications.
Its offerings include laboratory chemicals and reagents, consumables, equipment, instruments, production materials and related services. Avantor also provides supply-chain, procurement and other technical solutions designed to help customers manage laboratory and manufacturing operations.
Avantor serves customers across pharmaceutical and biopharmaceutical companies, healthcare providers, academic and government institutions, medical laboratories and industrial businesses.
Read More
- Five stocks we like better than Avantor
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
